Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
10.17
-0.35 (-3.35%)
Sep 29, 2026, 10:00 AM EDT - Market open
Pharming Group Revenue
Pharming Group had revenue of $366.45M in the twelve months ending June 30, 2026, up 7.84% year-over-year. In the year 2025, Pharming Group had annual revenue of $376.13M with 26.56% growth.
Revenue (ttm)
$366.45M
Revenue Growth
+7.84%
P/S Ratio
2.02
Revenue / Employee
$900,440
Employees
407
Market Cap
740.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.13M | 78.93M | 26.56% |
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Dec 31, 2019 | 189.39M | 34.10M | 21.96% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 3.12M | 406.76% |
| Dec 31, 2010 | 766.09K | 285.75K | 59.49% |
| Dec 31, 2009 | 480.35K | -445.02K | -48.09% |
| Dec 31, 2008 | 925.37K | -83.22K | -8.25% |
| Dec 31, 2007 | 1.01M | 815.16K | 421.44% |
| Dec 31, 2006 | 193.42K | -285.11K | -59.58% |
| Dec 31, 2005 | 478.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 132.42M |
| Verastem | 87.53M |
| Wave Life Sciences | 65.37M |
| DBV Technologies | 5.04M |
| Inventiva | 2.81M |
PHAR News
- 9 hours ago - Pharming announces CEO transition - GlobeNewsWire
- 4 days ago - Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS - GlobeNewsWire
- 7 days ago - Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 - GlobeNewsWire
- 14 days ago - Pharming Group Slides: Investor presentation - Filings
- 17 days ago - FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S. - GlobeNewsWire
- 20 days ago - Pharming Group to participate in September investor conferences - GlobeNewsWire
- 6 weeks ago - Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older - GlobeNewsWire
- 1 month ago - Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire